Group 1: Company Strategy and Development - The company will maintain a strategic focus on the fine chemical industry, emphasizing organic synthesis capabilities and enhancing customized services and proprietary products [1] - The company aims to promote healthy development through alliances and strategic partnerships [1] Group 2: Production and Project Updates - The Taizhou Lianhua's three fundraising projects are in normal trial production, with plans for a pilot workshop and multifunctional production workshop to commence construction, expected to be operational in the second half of 2015 [1] - The first project at Yancheng Lianhua is undergoing approval processes prior to trial production [1] - The new projects at Dezhou Lianhua are progressing, with a goal to launch three products by the end of 2014 [1] Group 3: Financial Performance and Product Insights - In 2013, the main source of new revenue and profit for Jiangsu Lianhua came from fundraising projects that commenced production that year [2] - Approximately 80% of the company's industrial revenue currently comes from pesticide intermediates, with plans to gradually increase the share of pharmaceutical intermediates in the future [2] - The company anticipates that pesticide business revenue will continue to grow, maintaining it as the primary income source for at least the next three years [2] Group 4: Environmental Investments and Challenges - The company invested over 100 million yuan in environmental facilities in 2013, which has impacted short-term performance [2] - The high environmental standards present challenges but are viewed as opportunities, with ongoing collaborations with international companies for environmental projects [2] Group 5: Sales and Revenue Generation - Taizhou Lianhua has commenced trial production, allowing for the sale of qualified products, which will generate sales revenue in the first half of the year [3]

Group 1: Project Developments - The first phase of the Texas Lianhua project has been completed on 260 acres, with the second phase currently in planning [1] - The design capacity of the phosgene facility in Texas Lianhua is set at a scale of 10,000 tons per year, with products including AKD, isocyanates, and acyl chlorides [1] - The Yancheng Lianhua pesticide project, ANBE, is currently in normal production and sales, generating expected benefits [1] Group 2: Business Improvements - The company is actively improving processes for AKD and other products, effectively reducing raw material costs and enhancing product quality [1] - The pharmaceutical intermediates business has faced slow development due to capacity, resource allocation, and market cycles, but new developments are anticipated with the completion of the Taizhou Lianhua plant and the establishment of a professional team [2] Group 3: Market Response - In response to recent significant fluctuations in the securities market, the company is formulating a plan to increase shareholding, demonstrating confidence in the capital market and the company's future [2]

Group 1: Company Development and Market Position - The company has a competitive advantage in customized chemical processing due to its strong capabilities in technology innovation, engineering construction, environmental facilities, and comprehensive management [1] - China plays a crucial role in the global chemical industry transition, with the company positioned to benefit from the outsourcing of production stages by multinational corporations [1] - The Jiangkou plant is designated as a new product incubation base, while the Taizhou plant focuses on pharmaceutical intermediates production [1][2] Group 2: Production Bases and Progress - The Taizhou plant officially commenced production in February 2015, with high-standard GMP multi-functional workshops under construction [2] - The company aims to obtain national pesticide production qualifications for its production bases in Yancheng and Jiangsu, with the first project starting trial production in March 2015 [2] - The Dezhou plant is actively developing downstream fine chemical projects to enhance production capacity [2] Group 3: Patent Expiry Impact - The company has products both under patent and nearing expiry, with varying impacts on business; generally, the price impact on original companies is significant, but the quantity impact is minimal [2] - Raw materials account for only 5%-10% of the final drug product price, indicating that price drops post-patent expiry do not primarily pressure custom service suppliers [2] Group 4: Business Strategy and Future Outlook - The trend of outsourcing pesticide and pharmaceutical intermediates in developed countries is expected to continue, providing growth opportunities for customized processing [2] - The company plans to focus on strategic alliances with major clients rather than entering formulation and terminal sales, while optimizing product structure to enhance profitability [2]

联化科技股份有限公司投资者关系活动记录表 证券代码：002250 证券简称：联化科技 编号：20150807 | --- | --- | --- | --- | --- | |-----------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------|------------------------------------------|--------| | | | | | | | 投资者关系活动类别 | □特定对象调研 | □分析师会议 | | | | | | □媒体采访 □业绩说明会 | | | | | | □新闻发布会 □路演活动 | | | | | | □现场参观 √其他（台湾机构投资者电话会议） | | | | 参与单位名称及人员 姓名 | 国泰证券 叶岦升 南山人寿 谢尚蓉 | | 练静彤 群益投信 洪玉婷 ...

Group 1: Project Updates - The Yancheng Lianhua project received government approval for trial production in March 2015 and is currently in normal production and sales, generating expected benefits [1] - Other projects are actively seeking approval, but the timeline for trial production permits is uncertain [1] Group 2: Safety and Environmental Concerns - The company emphasizes the importance of safety in the production of phosgene, a toxic gas, and has heightened safety awareness following the Tianjin hazardous chemical explosion [1][2] - The company is committed to strict adherence to environmental laws and regulations, implementing proactive measures to reduce pollution and enhance environmental protection as a core competitive advantage [2][3] Group 3: Management and Talent Acquisition - The addition of Mr. Andreas, with experience in multinational companies, is expected to enhance the company's management in areas such as R&D, quality control, and supply chain management [2] - The company plans to recruit more international talent to further its globalization efforts [2] Group 4: Business Performance and Outlook - The pharmaceutical and intermediate business, while currently small, has a stable profit model and sufficient product pipeline for future revenue [2] - The company expects a net profit growth of 10%-30% for the first nine months of 2015 compared to the same period last year [3] - Currency fluctuations, particularly the depreciation of the RMB, are anticipated to have a positive impact on the company's performance due to its primary business being export-oriented [2]

Group 1: Company Overview and Leadership - The new executive Andreas has joined the company to enhance its pharmaceutical and pharmaceutical intermediate business development [1][2] - The company has established strong partnerships with major international pharmaceutical companies, providing opportunities for growth [2][3] Group 2: Business Growth and Strategy - The company anticipates stable growth in its pesticide and pesticide intermediate business over the next 3 to 5 years [2][4] - The company is exploring mergers and acquisitions as part of its 2020 strategic plan, focusing on both pesticide and pharmaceutical sectors [2][3] Group 3: Service Offerings and Market Position - The company provides two types of services: customized product services and new service models, including R&D services [2][4] - The company positions itself as a leading CMO (Contract Manufacturing Organization) with a strong reputation in both domestic and international markets [4][5] Group 4: Market Dynamics and Challenges - The expiration of patents in the pharmaceutical industry is expected to have a significant price impact but limited quantity impact on the market [4][5] - The company is aware of the competitive landscape and aims to leverage its experience in pesticide production to enhance its pharmaceutical capabilities [4][5] Group 5: Environmental and Safety Investments - The company invested over 100 million in environmental protection in 2014, emphasizing the importance of sustainable development [5]

联化科技股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |---------------------------------|-----------------------------------------------------|--------|--------|-------|--------|---------------------|---------------------------|---------------|----------|--------|--------| | 证券代码： \n投资者关系活动类别 | 002250 \n□特定对象调研 | | | | | □分析师会议 | 证券简称：联化科技 编号： | | 20151028 | | | | | □媒体采访 □业绩说明会 | | | | | | | | | | | | | □新闻发布会 □路演活动 | | | | | | | | | | | | | □现场参观 √其他（投资者交流会--公司事业部发 ...

Group 1: Company Operations and Financial Goals - Taizhou Lianhua's three fundraising projects began trial production and sales in October 2014, with a revenue target of 200 million yuan for the year [1] - The second phase of the multifunctional workshop is designed by a foreign professional company and is expected to be completed and operational by October 2015 [1] - Yancheng Lianhua's first project faced delays in trial production due to environmental approval restrictions, with plans to obtain trial production permits by the end of November 2014 [1] Group 2: Regional Developments - Dezhou Lianhua's first phase covers over 200 acres and is operational, with the second phase design optimization planned to start construction after the Spring Festival [2] - Dezhou Lianhua's revenue is expected to grow compared to the previous year, with significant investments in safety facilities and systems [2] - Tianyu Chemical did not meet its performance targets in the first half of the year due to management and resource allocation issues, but adjustments have been made for better performance in the second half [2] Group 3: Competitive Advantages and Growth Strategy - The company's main competitive advantages lie in speed, service, quality, and flexibility, alongside ongoing technical upgrades and lean production management [2] - The company is open to mergers and acquisitions if they align with its strategic goals and product offerings [2]

联化科技股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |--------------------|----------------------------------------------|-------------------------------|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|------------------| | 证券代码： 002250 | | 证券简称：联化科技 | | 编号：20150428 | | | 投资者关系活动类别 | | | √特定对象调研 □分析师会议 | | | | | | | □媒体采访 □业绩说明会 | | | | | | | □新闻发布会 □路演活动 | | | | | | | | □现场 ...

联化科技股份有限公司投资者关系活动记录表 证券代码：002250 证券简称：联化科技 编号：20150528 | --- | --- | --- | --- | |-------------------------|--------------------------------------|-------------|----------------------------------------------------------------| | | | | | | 投资者关系活动类别 | √特定对象调研 | □分析师会议 | | | | □媒体采访 □业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | | | | □现场参观 □其他（投资者接待日活动） | | 参与单位名称及人员 姓名 | 首域投资(香港)有限公司 柯雷 陈希骅 | | | | 时间 | 2015 年 05 月 28 日 | | | | 地点 黄岩 | | | | | 上市公司接待人员姓 名 | 高级副总裁/董秘/财务总监 | | 陈飞彪 证券事务代表 任安立 | | 投资者关系活动主要 | 1. | | 公司的 ...